Targeted anti-mitotic therapies: can we improve on tubulin agents?

A new generation of promising anti-mitotic therapies that target proteins with specific functions in mitosis has been developed. As these drugs enter phase I and II trials, what do we know about their mechanism of action and their therapeutic range, and which patients will benefit?